ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study


Turhal N. S. , BAŞ E., Er O., Aliustaoglu M., Seber S., DANE F., ...Daha Fazla

JOURNAL OF BUON, cilt.15, ss.794-796, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 15 Konu: 4
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1007/s12032-010-9553-9
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.794-796

Özet

Purpose: Hepatocellular cancer (HCC) is a common malignancy with a high mortality rate. Existence of excisional repair cross complementation1 (ERCC1) is implicated in resistance to cisplatin treatment. Expression of ERCC1 in HCC is not known. In this study we aimed to find out whether a subset of HCC patients can be identified to benefit from cisplatin.